<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Change in target lesion sum of longest diameters from post-chemotherapy baseline to post-chemotherapy nadir</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Length of SLD Reduction (mm)</th>
    <th>BTH1677/
     <break/>Bevacizumab/Carboplatin/
     <break/>Paclitaxel
     <sup>a</sup>
     <break/>(
     <italic>N</italic> = 30)
    </th>
    <th>Bevacizumab/Carboplatin/
     <break/>Paclitaxel
     <sup>a</sup>
     <break/>(
     <italic>N</italic> = 13)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>&gt; 20</td>
    <td>2 (7%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>&gt; 10</td>
    <td>6 (20%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>&gt; 5</td>
    <td>10 (33%)</td>
    <td>2 (15%)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations: N</italic> overall sample size, 
   <italic>SLD</italic> sum of longest diameters
  </p>
  <p>
   <sup>a</sup>Number of patients continuing in study on maintenance therapy with at least 2 post-chemotherapy tumor assessments based on blinded central radiology review of the primary efficacy population
  </p>
 </table-wrap-foot>
</table-wrap>
